Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Qu, Shanqiang; Hu, Zhicheng; Zhang, Yi; Wang, Peng; Li, Shuting; Huang, Shaobin; Dong, Yunxian; Xu, Hailin; Rong, Yanchao; Zhu, Wenkai; Tang, Bin; Zhu, Jiayuan

doi:10.1089/wound.2020.1186

Cited by 16 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was suggested also in a previous similar meta‐analyses study which showed similar promising outcomes of platelet‐rich plasma in improving the hepatocellular carcinoma and reducing the complete‐healed diabetic foot ulcer wounds. 50 , 51 , 52 Well‐conducted randomised controlled trials are needed to assess these factors and the combination of different ages, ethnicity, and other variants of subjects; since our meta‐analysis study could not answer whether different ages, ethnicity, and gender are associated with the results.…”

Section: Discussionmentioning

confidence: 99%

Effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds: A meta‐analysis

Gong

Zhang

Gao

et al. 2022

International Wound Journal

View full text Add to dashboard Cite

We performed a meta‐analysis to evaluate the effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds. A systematic literature search up to March 2022 was performed and 1435 subjects with diabetic foot ulcer wounds at the baseline of the studies; 723 of them were treated with platelet‐rich plasma, and 712 used control. Odds ratio (OR) with 95% confidence intervals (CIs) was calculated to assess the effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds using the dichotomous method with a random or fixed‐effect model. The use of autologous platelet‐rich plasma resulted in significantly higher complete‐healed diabetic foot ulcer wounds compared with control (OR, 1.95; 95% CI, 1.49‐2.56, P < 0.001). The use of allogeneic platelet‐rich plasma resulted in significantly higher complete‐healed diabetic foot ulcer wounds compared with control (OR, 6.19; 95% CI, 2.32‐16.56, P < 0.001). The use of autologous and allogeneic platelet‐rich plasma resulted in significantly higher complete‐healed diabetic foot ulcer wounds compared with control. Though, the analysis of outcomes should be with caution because of the low number of studies in certain comparisons, for example, allogeneic platelet‐rich plasma compared with control.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds: A meta‐analysis

Gong

Zhang

Gao

et al. 2022

International Wound Journal

View full text Add to dashboard Cite

show abstract

“…Another study of 24 wounds showed that the size of 17 wounds was reduced by 90%, and 3 wounds was reduced by 80%–90% after PRP treatment ( 9 ). A recent meta-analysis of PRP in chronic refractory wounds, including seventeen randomized controlled trials, showed that compared with the control group, PRP significantly increased the percentage of healed wounds and the percentage of the healed area ( 11 ). All the studies showed the effectiveness of PRP and PRF in the treatment of chronic wounds.…”

Section: Discussionmentioning

confidence: 99%

“…All the studies showed the effectiveness of PRP and PRF in the treatment of chronic wounds. Autologous PRP was much safer than allogeneic PRP, although they were both effective in chronic refractory wounds ( 11 ). In this study, the combined use of autologous PRP injection and PRF filling resulted in a better wound healing rate than the use of PRP and PRF alone reported in the literature.…”

Section: Discussionmentioning

confidence: 99%

Local autologous platelet rich plasma injection combined with platelet rich fibrin filling as the main treatment for refractory wounds: A case series

Liu

Wei

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

Refractory wounds are a major global health problem that not only affects the quality of life, but also causes significant physical, psychological and economic burdens. How to promote wound healing has become the main goal of clinicians. To evaluate the safety and efficacy of local autologous platelet rich plasma (PRP) injection combined with platelet rich fibrin (PRF) filling as the main treatment for refractory wounds. In the study, autologous PRP and PRF were prepared from whole blood. Twelve patients, each having a refractory wound, were included. The wounds were debrided first to remove necrotic and infected tissues, and then were given once or twice local PRP injection combined with PRF filling treatment. The total healing time (the time from admission to wound healing) and the healing time after PRP/PRF combined treatment (the time from PRP treatment to wound healing), as well as the adverse events were recorded. The results showed that the wound duration before the combination treatment was 10.48 ± 3.66 weeks, and the mean area/volume (for sinus or fistula) of the wounds was 8.23 ± 2.67 cm2/9.54 ± 2.13 cm3 (for sinus or fistula). All wounds healed after once or twice PRP/PRF combined treatment. The total healing time was 26.91 ± 8.01 days, and the healing time after the combined treatment was 16.36 ± 7.47 days. No adverse events were reported during the treatment and follow-up period. Our case series demonstrate the safety and synergistic effectiveness of local autologous PRP injection combined with PRF filling as the main treatment for refractory wounds. Platelet concentrates is not only an adjuvant treatment for chronic wounds, but a potential substitute for chronic wounds, especially in sinuses and fistulas.

show abstract

“…Platelets play an important role in innate immunity since they degranulate and release antimicrobial peptides (AMPs) when activated [14,15]. Platelet rich plasma (PRP) is an autologous compound obtained from an individual's blood with numerous applications within the biomedical field [16][17][18][19][20][21][22][23][24]. Originally, PRP was found to be an effective treatment for musculoskeletal conditions such as osteoarthritis [25][26][27] or bone infections [28], among others [16][17][18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

“…Platelet rich plasma (PRP) is an autologous compound obtained from an individual's blood with numerous applications within the biomedical field [16][17][18][19][20][21][22][23][24]. Originally, PRP was found to be an effective treatment for musculoskeletal conditions such as osteoarthritis [25][26][27] or bone infections [28], among others [16][17][18][19][20][21][22][23][24]. As one of the main complications of traumatic lesions is potential subsequent bacterial infections [29][30][31], the discovery of the antimicrobial capacities of PRP brought great advantages to its utilization, since the application of a single compound could aid with multiple complications at a time such as pain relief [18], immune regulation [24] and bacterial control [27,[32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

Effect of BIO-PLYTM, a Platelet-Rich Plasma Derived Biologic on PRRSV-2-Infected Macrophages

Frias-De-Diego

Gilbertie

Scholle

et al. 2022

Viruses

View full text Add to dashboard Cite

Porcine Reproductive and Respiratory Syndrome (PRRS) is the one of the most devastating diseases impacting the swine industry worldwide. Control and prevention methods rely on biosafety measures and vaccination. As an RNA virus with a high rate of mutation, vaccines are only partially effective against circulating and newly emerging strains. To reduce the burden of this disease, research on alternative control methods is needed. Here, we assess the in vitro antiviral effect of a novel platelet-rich plasma-derived biologic termed BIO-PLYTM (for the BIOactive fraction of Platelet-rich plasma LYsate) from both swine and equine origin. Our results show that BIO-PLYTM significantly reduces the amount of PRRSV viral load determined by RT-qPCR and the number of infectious viral particles measured by TCID50 in infected porcine alveolar and parenchymal macrophages. This study also showed limited toxicity of BIO-PLYTM in vitro and aspects of its immunomodulatory capacity evaluating the regulation of reactive oxygen species and cytokines production in infected cells. Finally, this study presents promising data on the effect of BIO-PLYTM on other RNA viruses such as human A influenza viruses and coronavirus.

show abstract

Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cited by 16 publications

References 40 publications

Effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds: A meta‐analysis

Effect of platelet‐rich plasma vs standard management for the treatment of diabetic foot ulcer wounds: A meta‐analysis

Local autologous platelet rich plasma injection combined with platelet rich fibrin filling as the main treatment for refractory wounds: A case series

Effect of BIO-PLYTM, a Platelet-Rich Plasma Derived Biologic on PRRSV-2-Infected Macrophages

Contact Info

Product

Resources

About